




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07H 17/08, A61K 31/70	A1	(11) International Publication Number: WO 00/63223 (43) International Publication Date: 26 October 2000 (26.10.00)
(21) International Application Number: PCT/HR00/00009 (22) International Filing Date: 19 April 2000 (19.04.00) (30) Priority Data: P990116A 20 April 1999 (20.04.99) HR (71) Applicant (for all designated States except US): PLIVA, FARMACEUTSKA INDUSTRIJA, DIONIČKO DRUŠTVO [HR/HR]; Ulica grada Vukovara 49, 10000 Zagreb (HR). (72) Inventors; and (75) Inventors/Applicants (for US only): LAZAREVSKI, Gorjana [HR/HR]; Barutanski jarak 18, 10000 Zagreb (HR). ALI-HODŽIĆ, Sulejman [HR/HR]; Šmarjetski put 6, 10000 Zagreb (HR). KOBREHEL, Gabrijela [HR/HR]; Dobriše Cesačića 8, 10000 Zagreb (HR). MUTAK, Stjepan [HR/HR]; Jagredje 1, 10000 Zagreb (HR). (74) Agent: PLIVA D.D. PRAVNI POSLOVI; Vesna Vasiljevic, Ulica grada Vukovara 49, 10000 Zagreb (HR).		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: NOVEL 8A- AND 9A-15-MEMBERED LACTAMS



(57) Abstract

The invention relates to novel 15-membered 8a- and 9a-lactams from the class of 6-O-methyl-erythromycin A of general formula (I), their pharmaceutically acceptable addition salts with inorganic or organic acids and their hydrates, wherein A stands for NH group and B simultaneously stands for C=O group, or A stands for C=O group and B simultaneously stands for NH group, and the radicals R¹, R², R³, R⁴, R⁵, R⁶ have the meaning given in claim 1.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

NOVEL 8A- AND 9A-15-MEMBERED LACTAMS

Technical Field of the Invention

A61K 31/70, C07H 17/08

Technical Problem

The invention relates to novel 15-membered 8a- and 9a-lactams from the class of the macrolide antibiotic 6-*O*-methyl-erythromycin A, to intermediates for their preparation, to a process for their preparation, to their pharmaceutically acceptable addition salts with inorganic and organic acids, to their hydrates, to a process for the preparation of pharmaceutical compositions as well as to the use of pharmaceutical compositions for treatment of bacterial infections.

Prior Art

Erythromycin A is a macrolide antibiotic, whose structure is characterized by a 14-membered lactone ring with C-9 ketone and two sugars, L-cladinose and D-desosamine, glycosidically bound in C-3 and C-5 positions onto an aglycone moiety of the molecule (McGuire, Antibiot. Chemother. 1952; 2:281). By an oximation of C-9 ketone with hydroxylamine hydrochloride, by Beckmann rearrangement of the obtained 9(*E*)-oxime and by a reduction of the formed 6,9-imino ether there is obtained 9-deoxo-9a-aza-9a-homoerythromycin A, the first semisynthetic macrolide with a 15-membered azalactone ring (Kobrehel G. et al., US 4,328,334, 5/1982). By means of a reductive methylation of 9a-amino group, azithromycin, a prototype of a novel class of 9a-azalide antibiotics was synthesized (Kobrehel G. et al., BE 892 357, 7/1982). In addition to having a broad antimicrobial spectrum including also Gram-negative bacteria, azithromycin is also characterized by a long biological half-life, a specific transport mechanism to the site of use and a short therapy time. Azithromycin easily penetrates and accumulates inside human fagocyte cells resulting in improved activity on intracellular pathogenic microorganisms from classes *Legionella*, *Chlamydia* and *Helicobacter*.

It is known as well that by a *O*-methylation of C-6 hydroxyl group clarithromycin (6-*O*-methyl-erythromycin A) is obtained (Morimoto S. et al., J. Antibiotics 1984, 37, 187). In relation to erythromycin A, clarithromycin is much more stable in acidic medium and exhibits improved *in vitro* activity against Gram-positive bacterial strains (Kirst H. A. et al., Antimicrobial Agents and Chemother., 1989, 1419).

By recent research on 14-membered macrolides, a novel type of macrolide antibiotics, ketolides, has been discovered, whose structure is characterized by a 3-keto group instead of a neutral sugar, L-cladinose (Agouridas C. et al., EP 596802 A1 5/1994; Le Martret O., FR 2697524 A1 5/94). Ketolides exhibit significantly improved *in vitro* activity against MLS (macrolide, lincosamide and streptogramin B) induced-resistant organisms (Jamjian C., Antimicrob. Agents Chemother., 1997, 41, 485).


It has been described as well that by Beckmann rearrangement of 6-*O*-methyl-erythromycin A 9(*E*)- and 9(*Z*)-oximes, hydrolysis of cladinose of the obtained 8a- and 9a-lactams, protection of 2'-hydroxyl group of desosamine, an acylation reaction, an oxidation of 3-hydroxyl group and by deprotection, there are obtained 15-membered 8a- and 9a- ketolides from the class of 6-*O*-methyl-erythromycin A (Lazarevski G. et al., PCT/HR 99/00004, 4/99).

According to known and established prior art, novel 15-membered 8a- and 9a-lactams from the class of 6-*O*-methyl-erythromycin A, which are the object of the present invention, their pharmaceutically acceptable addition salts with organic or inorganic acids, their hydrates, methods and intermediates for their preparation and methods for their preparation and use as pharmaceutical preparations have hitherto not been described. The object of this invention is preparation of 11,12-substituted derivatives of 6-*O*-methyl-erythromycin A 8a- and 9a-lactams and their 3-hydroxy and 3-keto derivatives. A further object of the present invention are 3-acyl derivatives of 6-*O*-methyl-erythromycin A 8a- and 9a-lactams and 3-acyl-derivatives of 11,12-substituted 6-*O*-methyl-erythromycin A 8a- and 9a-lactams. Novel 15-membered 8a- and 9a-

lactams of the present invention are potential antibiotics for the treatment of Gram-positive and Gram-negative susceptible resistant strains.

Description of Technical Problem with Examples

Novel 15-membered 8a- and 9a-lactams from the class of 6-*O*-methyl-erythromycin A of the general formula (I)




their pharmaceutically acceptable addition salts with inorganic or organic acids and their hydrates, wherein


A stands for NH group and **B** simultaneously stands for C=O group, or

A stands for C=O group and **B** simultaneously stands for NH group,

R¹ stands for OH group, L-cladinosyl group of formula (II)



or R^1 stands for a group of formula (III),



wherein

Y stands for hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkyl group with at least one incorporated O, N or S atom or Y stands for $(CH_2)_n$ -Ar, wherein $(CH_2)_n$ stands for alkyl and n stands for 1-10, with or without incorporated O, N or S atoms, and Ar stands for 5-10-membered monocyclic or bicyclic aromatic ring containing 0-3 O, N or S atoms, which is unsubstituted or substituted with 1-3 groups representing halogen, OH, OMe, NO_2 , NH_2 , amino- C_1 - C_3 alkyl, amino- C_1 - C_3 dialkyl, CN, SO_2NH_2 , C_1 - C_3 alkyl, or

R^1 together with R^2 stands for ketone,

R^2 stands for hydrogen or together with R^1 stands for ketone,



R^3 stands for hydrogen or C_1 - C_4 alkanoyl group,

R^4 stands for hydrogen or together with R^5 stands for ketone,

R^5 stands for OH, NH_2 , amino- C_1 - C_3 alkyl or amino- C_1 - C_3 dialkyl, $O(CH_2)_n$ Ar or $S(CH_2)_n$ Ar, wherein $(CH_2)_n$ and Ar have the above meanings, or together with R^4 stands for ketone,

R^6 stands for hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkyl group with at least one incorporated O, N or S atom, or $(CH_2)_n$ -Ar group, wherein $(CH_2)_n$ and Ar have the above meanings, or

R^5 and R^6 together with intervening atoms form an additional ring of formula (IV)



wherein

Z stands for CH₂, C=O, C(NH), SO, SO₂, CH₂CO, COCH₂, CH₂CH₂CO, COCH₂CH₂ or CH₂CH₂, and

X stands for hydrogen, C₁-C₃ alkyl, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl or (CH₂)_n-Ar group, wherein (CH₂)_n and Ar have the above meanings,

are obtained as follows:

Step 1:

The first step of the invention includes a reaction of 6-*O*-methyl-9a-aza-9a-homoerythromycin A or 6-*O*-methyl-8a-aza-8a-homoerythromycin A, obtained according to PCT/HR 99/00004, 4/99, with ethylene carbonate in the presence of inorganic or organic bases, preferably potassium carbonate, in a reaction-inert solvent, preferably in ethyl acetate, yielding corresponding 11,12-cyclic carbonates of the general formula (I), wherein **A** stands for NH and **B** simultaneously stands for C=O group, or **A** stands for C=O group and **B** simultaneously stands for NH group, **R**¹ stands for L-cladinosyl group of formula (II) and **R**², **R**³ and **R**⁴ are mutually the same and stand for hydrogen, **R**⁵ and **R**⁶ together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O group.

Step 2:

11,12-cyclic carbonates obtained in the Step 1, are subjected to hydrolysis with strong acids, preferably with 0.25 - 1.5 N hydrochloric acid, in a mixture of water and lower alcohols, preferably methanol, ethanol or isopropanol, over 10-30 hours at room temperature, yielding 3-decladinosyl derivatives of general formula (I), wherein **A** stands for NH group and **B** simultaneously stands for C=O group, or **A** stands for C=O group and **B** simultaneously stands for NH group, **R**¹ stands for OH group, **R**², **R**³ and **R**⁴ are mutually the same and stand for hydrogen, and **R**⁵ and **R**⁶ together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O group.

Step 3:

3-Decladinosyl derivatives from the Step 2 are subjected to a selective acylation of the hydroxyl group in 2'-position. Acylation is carried out with chlorides or anhydrides of carboxylic acids with up to 4 carbon atoms, preferably with acetic acid anhydride, in the presence of inorganic or organic bases, in a reaction-inert solvent at a temperature from 0 - 30°C, yielding 2'-O-acyl derivatives of the general formula (I), wherein A stands for NH group and B simultaneously stands for C=O group, or A stands for C=O group and B simultaneously stands for NH group, R^1 stands for OH group, R^2 and R^4 are mutually the same and stand for hydrogen, R^3 stands for acetyl and R^5 and R^6 together with intervening atoms form an additional ring of formula (IVb), wherein Z stands for C=O group.

As suitable bases sodium hydrogen carbonate, sodium carbonate, potassium carbonate, triethylamine, pyridine, tributylamine, preferably sodium hydrogen carbonate are used. As a suitable inert solvent methylene chloride, dichloroethane, acetone, pyridine, ethyl acetate, tetrahydrofuran, preferably methylene chloride is used.

Step 4:

2'-Acetyl derivatives from the Step 3 are optionally subjected to a reaction with mixed anhydrides of carboxylic acids of formula Y-COO-R', wherein Y stands for hydrogen, C₁-C₆ alkyl, C₁-C₆ alkyl group with at least one incorporated O, N or S atom, or Y stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n is 1-10, without or with incorporated O, N or S atoms, and Ar stands for 5-10-membered monocyclic or bicyclic aromatic ring comprising 0-3 O, N or S atoms, which is unsubstituted or substituted with 1-3 groups representing halogen, OH, OMe, NO₂, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl, CN, SO₂NH₂, C₁-C₃ alkyl and R' is a group which is usually used for the preparation of mixed anhydrides such as pivaloyl, p-toluenesulfonyl, isobutoxycarbonyl, ethoxycarbonyl or isopropoxycarbonyl group, in the presence of inorganic or organic bases, in a reaction-inert solvent, preferably in methylene chloride, at a temperature from 0 - 30 °C for 3 - 100 hours, yielding 3-acyl derivatives of general formula (I), wherein R^1 stands for a group of formula (III),

wherein **Y** has the above meanings, **A** stands for NH group and **B** simultaneously stands for C=O group, or **A** stands for C=O group and **B** simultaneously stands for NH group, **R**² and **R**⁴ are mutually the same and stand for hydrogen, **R**³ stands for acetyl and **R**⁵ and **R**⁶ together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O group, which are subsequently subjected to deprotection with lower alcohols, preferably in methanol, at a temperature from room temperature to the reflux temperature of the solvent, yielding a compound of the general formula (I), wherein **R**³ stands for hydrogen and all remaining substituents have the above meanings.

Step 5:

2'-Acetyl derivatives from the Step 3 are optionally subjected to oxidation of the hydroxyl group in C-3 position of an aglycone ring according to a modified Moffat-Pfitzner process with *N,N*-dimethyl aminopropyl-3-ethyl-carbodiimide in the presence of dimethyl sulfoxide and pyridinium trifluoroacetate as a catalyst in an inert organic solvent, preferably in methylene chloride, at a temperature from 10°C to room temperature, yielding 3-oxo derivatives of the general formula (I), wherein **A** stands for NH group and **B** simultaneously stands for C=O group, or **A** stands for C=O group and **B** simultaneously stands for NH group, **R**¹ together with **R**² stands for ketone, **R**³ stands for acetyl, **R**⁴ stands for hydrogen and **R**⁵ and **R**⁶ together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O group, which are subsequently subjected to deprotection in lower alcohols, preferably in methanol, at a temperature from room temperature to the reflux temperature of the solvent, yielding a compound of the general formula (I), wherein **R**³ stands for hydrogen and all remaining substituents have the above meanings.

Step 6:

By subjecting 6-*O*-methyl-9a-aza-9a-homoerythromycin A or 6-*O*-methyl-8a-aza-8a-homoerythromycin A obtained according to PCT/HR 99/00004, 4/99, to hydrolysis with strong acids as described in the Step 2, followed by a selective acylation of 2'-position as in the Step 3 and by a reaction with mixed anhydrides as in the Step 4,

there are obtained compounds of the general formula (I), wherein R^1 has the meaning of a group of the formula (III), wherein Y stands for hydrogen, C_1-C_6 alkyl, C_1-C_6 alkyl group with at least one incorporated O, N or S atom, or Y stands for $(CH_2)_n-Ar$, wherein $(CH_2)_n$ stands for alkyl and n stands for 1-10, without or with incorporated O, N or S atoms, and Ar stands for 5-10-membered monocyclic or bicyclic aromatic ring containing 0-3 O, N or S atoms, which is unsubstituted or substituted with 1-3 groups representing halogen, OH, OMe, NO_2 , NH_2 , amino- C_1-C_3 -alkyl or amino- C_1-C_3 dialkyl, CN, SO_2NH_2 , C_1-C_3 alkyl, R^2 , R^3 , R^4 , and R^6 are mutually the same and stand for hydrogen and R^5 is OH group.

Step 7:

By subjecting 6-*O*-methyl-9a-aza-9a-homoerythromycin A or 6-*O*-methyl-8a-aza-8a-homoerythromycin A obtained according to PCT/HR 99/00004, 4/99, to hydrolysis with strong acids as described in the Step 2, followed by a selective acylation of 2'-position as in the Step 3 and by oxidation and deprotection as in the Step 5, after purification with low pressure chromatography on a silica gel column using the system ethyl acetate-(*n*-hexane)-diethyl amine 10:10:2 and by subsequent evaporation of chromatographically homogeneous fractions with lower R_f and rechromatography in the system $CH_2Cl_2-CH_3OH-conc.NH_4OH$ 90:9:0.5, there is obtained a compound of the general formula (I), wherein A stands for NH group and B simultaneously stands for C=O group or A stands for C=O group and B simultaneously stands for NH group, R^1 together with R^2 stands for a ketone, R^3 and R^6 are mutually the same and stand for hydrogen and R^4 together with R^5 stands for a ketone.

Alternatively, compounds from the Step 4 can be obtained by subjecting the compounds from the Step 6 to a reaction with ethylene carbonate in a manner as described in the Step 1.

Alternatively, the compounds from the Step 2 can be obtained by changing the sequence of the reaction steps in such a manner that 6-*O*-methyl-9a-aza-9a-homoerythromycin A or 6-*O*-methyl-8a-aza-8a-homoerythromycin A obtained

according to PCT/HR 99/00004, 4/99, are first subjected to a hydrolysis with strong acids as described in the Step 2 and then to a reaction with ethylene carbonate in a manner described in the Step 1.

Alternatively, the compounds of the Step 5 can be obtained in such a manner that 3-decladinosyl-3-oxo-6-*O*-methyl-9a-aza-9a-homoerythromycin A or 3-decladinosyl-3-oxo-6-*O*-methyl-8a-aza-8a-homo-erythromycin A obtained according to PCT/HR 99/00004, 4/99, are subjected to a reaction with ethylene carbonate in the manner described in the Step 1.

Pharmaceutically acceptable addition salts which are also an object of the present invention, are obtained by a reaction of novel compounds from the class of 6-*O*-methyl-9a-aza-9a-homo- and 6-*O*-methyl-8a-aza-8a-homo-erythromycins A of the general formula (I), wherein A, B, R¹, R², R³, R⁴, R⁵ and R⁶ have the above meanings, with an at least equimolar amount of a suitable corresponding inorganic or organic acid such as hydrochloric, hydroiodic, sulfuric, phosphoric, acetic, propionic, trifluoroacetic, maleic, citric, stearic, succinic, ethylsuccinic, methanesulfonic, benzenesulfonic, p-toluenesulfonic, laurylsulfonic acid and the like, in a reaction-inert solvent. Addition salts are isolated by filtration if they are insoluble in the reaction-inert solvent, by precipitation by means of a non-solvent or by evaporation of the solvent, most frequently by lyophilization.

The process is illustrated by the following examples which do not limit the scope of the invention in any way.

Example 1**6-*O*-Methyl-9a-aza-9a-homoerythromycin A 11,12-cyclic carbonate**

To ethyl acetate (80 ml) 6-*O*-methyl-9a-aza-9a-homoerythromycin A (3 g, 0.0039 mole) obtained according PCT/HR 99/00004, 4/99, K₂CO₃ (9 g, 0.0651 mole) and ethylene carbonate (9 g, 0.1022 mole) were added and then the reaction mixture was stirred under heating at reflux temperature for 12 hours. The reaction suspension was diluted with ethyl acetate (100 ml) and rinsed with saturated NaCl solution (100 ml) and water (200 ml). The evaporation of the organic solvent gave an oily residue, from which by low-pressure chromatography on a silica gel column using the system CH₂Cl₂-CH₃OH-conc.NH₄OH, 90:9:1.5 the title product (2 g) was obtained.

IR (KBr) cm⁻¹ 3452, 2974, 2939, 2833, 2787, 1815, 1737, 1668, 1531, 1456, 1379, 1287, 1168, 1111, 1053, 1014, 955, 903.

¹H NMR (300 MHz, CDCl₃) δ 5.76 (9a-CONH), 5.10 (H-1"), 4.87 (H-13), 4.41 (H-1'), 4.31 (H-10), 4.20 (H-11), 4.03 (H-5"), 3.97 (H-3), 3.65 (H-5), 3.47 (H-5'), 3.34 (3"-OCH₃), 3.18 (H-2'), 3.14 (6-OCH₃), 3.02 (H-4"), 2.84 (H-2), 2.43 (H-3'), 2.33 (H-2"a), 2.28 /3'-N(CH₃)₂/, 2.19 (H-8), 2.28 (H-7a), 2.19 (H-4), 1.79 (H-14a), 1.65 (H-4'a), 1.57 (H-2"b), 1.56 (H-14b), 1.49 (12-CH₃), 1.38 (6-CH₃), 1.29 (5"-CH₃), 1.27 (H-7b), 1.24 (3"-CH₃), 1.21 (5'-CH₃), 1.20 (H-4'b), 1.20 (2-CH₃), 1.18 (10-CH₃), 1.07 (4-CH₃), 1.06 (8-CH₃), 0.90 (15-CH₃).

¹³C NMR (75 MHz, CDCl₃) δ 178.4 (C-9), 177.2 (C-1), 153.9 (C=O carbonate), 102.7 (C-1'), 94.0 (C-1"), 84.7 (C-12), 83.6 (C-11), 79.1 (C-5), 78.7 (C-6), 77.9 (C-4"), 75.5 (C-3), 75.2 (C-13), 72.6 (C-3"), 70.7 (C-2'), 68.5 (C-5'), 65.3 (C-5"), 65.1 (C-3'), 51.0 (6-OCH₃), 49.2 (3"-OCH₃), 44.9 (C-2), 44.3 (C-10), 42.0 (C-4), 40.1 /3'-N(CH₃)₂/, 39.4 (C-7), 36.2 (C-8), 34.3 (C-2"), 28.6 (C-4'), 21.8 (C-14), 21.3 (3"-CH₃), 21.1 (5'-CH₃), 21.0 (6-CH₃), 19.6 (8-CH₃), 18.0 (5"-CH₃), 14.1 (2-CH₃), 13.0 (10-CH₃), 12.8 (12-CH₃), 10.2 (15-CH₃), 9.1 (4-CH₃).

Example 2**3-Decladinosyl-3-oxy-6-*O*-methyl-9a-aza-9a-homoerythromycin A
11,12-cyclic carbonate**

In 0.25 *N* hydrochloric acid (45 ml) the substance from the Example 1 (1.5 g, 0.002 mole) was dissolved and it was left standing at room temperature for 48 hours. Onto the reaction mixture CH₂Cl₂ (30 ml, pH 1.5) was added, the pH of the mixture was adjusted with conc. NH₄OH to pH 9.0, the layers were separated and the aqueous one was extracted two more times with CH₂Cl₂ (30 ml). The combined organic extracts were rinsed with 10% aqueous NaHCO₃ solution and water and evaporated, yielding 3-decladinosyl-3-oxy-6-*O*-methyl-9a-aza-9a-homoerythromycin A 11,12-cyclic carbonate (1.1 g)

IR (KBr) cm⁻¹ 3440, 2974, 2939, 1822, 1729, 1650, 1525, 1457, 1380, 1241, 1167, 1113, 1073, 1047, 983.

FAB-MS *m/z* 731 (MH⁺).

Example 3**2'-*O*-Acetyl-3-decladinosyl-3-oxy-6-*O*-methyl-9a-aza-9a-homoerythromycin A
11,12-cyclic carbonate**

To a solution of 3-decladinosyl-3-oxy-6-*O*-methyl-9a-aza-9a-homoerythromycin A 11,12-cyclic carbonate from the Example 2 (1.0 g, 0.0016 mole) in CH₂Cl₂ (100 ml), NaHCO₃ (0.62 g, 0.0074 mole) and acetic acid anhydride (0.36 ml, 0.0038 mole) were added and it was then stirred for 4 hours at room temperature. Onto the reaction mixture a saturated NaHCO₃ solution (50 ml) was added, the layers were separated and the aqueous one was extracted two more times with CH₂Cl₂ (20 ml). The combined organic extracts were rinsed with a saturated NaHCO₃ solution and water and evaporated, yielding the title product (1.15 g) with the following physical-chemical constants:

IR (KBr) cm^{-1} 3444, 2975, 2936, 1816, 1737, 1666, 1539, 1461, 1376, 1237, 1166, 1113, 1046, 1015, 985, 943.

^1H NMR (300 MHz, CDCl_3) δ 6.97 (9a-CONH), 4.97 (H-13), 4.80 (H-2'), 4.69 (H-1'), 4.29 (H-11), 4.27 (H-10), 3.89 (H-5), 3.62 (H-3), 3.53 (H-5'), 3.22 (6-OCH₃), 2.87 (H-3'), 2.74 (H-2), 2.30 /3'-N(CH₃)₂/, 2.30 (H-8), 1.98 (H-4), 1.81 (H-7a), 1.86 (H-14a), 1.78 (H-4'a), 1.64 (H-14b), 1.41* (12-CH₃), 1.35 (H-4'b), 1.30 (2-CH₃), 1.30 (H-7b), 1.29* (6-CH₃), 1.26 (5'-CH₃), 1.19 (10-CH₃), 1.12 (8-CH₃), 0.94 (4-CH₃), 0.92 (15-CH₃).

^{13}C NMR (75 MHz, CDCl_3) δ 178.4 (C-1)*, 177.2 (C-9)*, 170.0 (2'-COCH₃), 153.3 (C=O carbonate), 99.3 (C-1'), 85.5 (C-12), 83.8 (C-11), 79.6 (C-6), 78.8 (C-5), 76.9 (C-13), 76.5 (C-3), 70.9 (C-2'), 68.5 (C-5'), 62.5 (C-3'), 50.2 (6-OCH₃), 43.9 (C-2), 43.8 (C-10), 39.9 /3'-N(CH₃)₂/, 38.9 (C-7), 36.7 (C-4), 34.1 (C-8), 30.8 (C-4'), 21.7 (C-14), 20.8 (5'-CH₃), 21.1 (2'-CONH₃), 19.1 (6-CH₃), 18.1 (8-CH₃), 17.5 (10-CH₃), 15.4 (2-CH₃), 12.2 (12-CH₃), 10.0 (15-CH₃), 7.7 (4-CH₃).

Example 4

3-Decladinosyl-3-oxo-6-O-methyl-9a-aza-9a-homoerythromycin A

11,12-cyclic carbonate

To a solution of 2'-O-acetyl-3-decladinosyl-3-oxy-6-O-methyl-9a-aza-9a-homoerythromycin A 11,12-cyclic carbonate from the Example 3 (1 g, 0.0015 mole) in CH_2Cl_2 (20 ml), dimethyl sulfoxide (2.5 ml) and *N,N*-dimethyl-aminopropyl-ethylcarbodiimide (2.64 g, 0.014 mole) were added. The reaction mixture was cooled to 15°C and then, under stirring and maintaining the temperature, a pyridinium trifluoroacetate solution (2.7 g, 0.014 mole) in CH_2Cl_2 (12 ml) was gradually added drop by drop during 1 hour. The temperature of the reaction mixture was gradually raised to room temperature, it was kept stirring for further 4 hours and the reaction was ceased by the addition of a saturated NaCl solution (20 ml) and CH_2Cl_2 (20 ml). After alkalizing to pH 9.5 (2*N* NaOH), the reaction mixture was extracted with CH_2Cl_2 and the organic extracts were rinsed with a saturated NaCl solution and water

and dried over K_2CO_3 . After filtration and evaporation of methylene chloride at a reduced pressure, an oily residue was obtained, which was subjected to methanolysis (70 ml) for 24 hours at room temperature. Methanol was evaporated at a reduced pressure and the obtained residue was purified by low-pressure chromatography on a silica gel column using chloroform and then the solvent system $CHCl_3$ - CH_3OH -conc. NH_4OH , 6:1:0.1. By evaporation of chromatographically homogeneous fractions, the title product (0.2 g) with the following physical-chemical constants was obtained:

IR (KBr) cm^{-1} 3442, 3380, 2975, 2940, 2881, 2840, 2787, 1813, 1750, 1717, 1666, 1586, 1526, 1458, 1381, 1325, 1237, 1166, 1111, 1079, 1050, 1017, 991, 957.

1H NMR (300 MHz, $CDCl_3$) δ 6.39 (9a-CONH), 4.96 (H-13), 4.44 (H-1'), 4.34 (H-10), 4.21 (H-11), 4.14 (H-5), 3.94 (H-2), 3.60 (H-5'), 3.27 (H-4), 3.20 (H-2'), 2.85 (6-OCH₃), 2.50 (H-3'), 2.27 /3'-N(CH₃)₂/, 2.27 (H-8), 2.27 (H-7a), 1.84 (H-14a), 1.67 (H-4'a), 1.62 (H-14b), 1.52 (6-CH₃), 1.45 (2-CH₃), 1.45 (H-7b), 1.34 (4-CH₃), 1.27 (12-CH₃), 1.24 (5'-CH₃), 1.23 (H-4'b), 1.22 (10-CH₃), 1.12 (8-CH₃), 0.91 (15-CH₃).

^{13}C NMR (75 MHz, $CDCl_3$) δ 206.7 (C-3), 177.0 (C-9)*, 170.1* (C-1), 153.6 (C=O carbonate), 103.4 (C-1'), 84.4 (C-12), 84.1 (C-11), 78.5 (C-5), 78.1 (C-6), 75.7 (C-13), 70.1 (C-2'), 69.2 (C-5'), 65.4 (C-3'), 50.1 (6-OCH₃), 50.0 (C-2), 47.7 (C-4), 44.2 (C-10), 39.9 /3'-N(CH₃)₂/, 39.1 (C-7), 36.2 (C-8), 28.0 (C-4'), 21.7 (C-14), 20.9 (5'-CH₃), 20.5 (12-CH₃), 19.8 (8-CH₃), 16.3 (2-CH₃), 14.8 (4-CH₃), 13.6 (10-CH₃), 13.0 (6-CH₃), 10.0 (15-CH₃).

Example 5

3-Decladinosyl-3-oxy-6-O-methyl-9a-aza-9a-homoerythromycin A 11,12-cyclic carbonate

By a reaction of 3-decladinosyl-3-oxy-6-O-methyl-9a-aza-9a-homoerythromycin A and ethylene carbonate according to the process described in the Example 1, 3-decladinosyl-3-oxy-6-O-methyl-9a-aza-9a-homoerythromycin A 11,12-cyclic carbonate with the physical-chemical constants as given in the Example 2 was obtained.

Example 6**3-Decladinosyl-3-*O*-(4-nitrophenyl)acetyl-6-*O*-methyl-9a-aza-9a-homoerythromycin A 11,12-cyclic carbonate**

To a solution of 4-nitrophenyl acetic acid (0.263 g, 0.0015 mole) in dry CH₂Cl₂ (5 ml), triethylamine (0.202 ml, 0.0015 mole) was added and it was cooled to 0°C. To the reaction mixture pivaloyl chloride (0.180 ml, 0.0015 mole) was added, it was stirred for 30 minutes at the same temperature and then pyridine (0.4 ml) and a solution of 2'-*O*-acetyl-3-decladinosyl-3-oxy-6-*O*-methyl-9a-aza-9a-homoerythromycin A 11,12-cyclic carbonate from the Example 3 (0.3 g, 0.0004 mole) were added. It was stirred at the same temperature for further 3 hours, to the reaction mixture a saturated NaCl solution (20 ml) was added, the layers were separated and the aqueous one was extracted two more times with CH₂Cl₂ (20 ml). The combined organic extracts were dried over K₂CO₃ and evaporated at a reduced pressure. Onto the oily residue methanol (30 ml) was added and it was left standing at room temperature over night. Methanol was evaporated at a reduced pressure and the obtained residue was purified by chromatography on a silica gel column using the system CH₂Cl₂-CH₃OH-conc.NH₄OH, 90:4:0.5 and by crystallisation from a mixture methylene chloride-ether-(n-hexane), whereby a chromatographically homogeneous title product was obtained.

IR (KBr) cm⁻¹ 3417, 3380, 2975, 2939, 1813, 1750, 1742, 1669, 1524, 1526, 1458, 1348, 1167, 1076, 1046.

Example 7**3-Decladinosyl-3-*O*-(4-nitrophenyl)acetyl-6-*O*-methyl-9a-aza-9a-homoerythromycin A**

By reacting 2'-*O*-acetyl-3-decladinosyl-3-oxy-6-*O*-methyl-9a-aza-9a-homoerythromycin A (0.3 g, 0.0004 mole) obtained according to the process described in PCT/HR 99/00004, 4/99, 4-nitrophenyl acetic acid (0.263 g, 0.0015 mole) and pivaloyl chloride (0.180 ml, 0.015 mole), there was obtained according to the process described in the

Example 6, a chromatographically homogeneous title product with the following physical-chemical constants:

IR (KBr) cm^{-1} 3396, 2976, 2941, 2879, 2791, 1732, 1698, 1669, 1601, 1521, 1456, 1380, 1346, 1232, 1182, 1111, 1073, 1051, 983.

FAB-MS m/z 768 (MH^+).

Example 8

3-Decladinosyl-3,11-dioxo-6-*O*-methyl-9a-aza-9a-homoerythromycin A

To a solution of 2'-*O*-acetyl-3-decladinosyl-3-oxy-6-*O*-methyl-9a-aza-9a-homoerythromycin A (0.760 g, 0.0012 mole) obtained according to the process described in PCT/HR 99/00004, 4/99, in CH_2Cl_2 (25 ml), dimethyl sulfoxide (2.5 ml) and *N,N*-dimethyl-aminopropyl-ethyl-carbodiimide (2.7 g, 0.014 mole) were added. The reaction mixture was cooled to 15°C and then, under stirring and maintaining the temperature, gradually drop by drop a solution of pyridinium trifluoroacetate (2.75 g, 0.0014 mole) in CH_2Cl_2 (10 ml) was added over 45 minutes. The temperature of the reaction mixture was gradually raised to room temperature, the mixture was stirred for further 10 hours and then the reaction was ceased by the addition of a saturated NaCl solution (25 ml) and CH_2Cl_2 (25 ml). After alkalizing with 2 *N* NaOH to pH 9.5, the reaction mixture was extracted with CH_2Cl_2 , the organic extracts were subsequently rinsed with a saturated NaCl solution, NaHCO_3 and water and dried over K_2CO_3 . After filtration and evaporation of CH_2Cl_2 at a reduced pressure, a product (1.2 g) was obtained. The oily residue was subjected to methanolysis (50 ml) for 24 hours at room temperature. Methanol was evaporated at a reduced pressure and the obtained residue was purified by low-pressure chromatography on a silica gel column using the system ethyl acetate-(*n*-hexane)-diethyl amine, 10:10:2. By evaporation of chromatographically homogeneous fractions with lower R_f and by rechromatography in the system CH_2Cl_2 - CH_3OH -conc. NH_4OH , 90:9:0.5, a chromatographically homogeneous title product with the following physical-chemical constants was obtained:

IR (KBr) cm^{-1} 3291, 2975, 2940, 2879, 2788, 1732, 1715, 1661, 1557, 1457, 1378, 1339, 1300, 1264, 1174, 1110, 1079, 1051, 1010, 982.

^1H NMR (300 MHz, CDCl_3) δ 7.57 (9a-CONH), 5.05 (H-10), 4.85 (H-13), 4.62 (H-5), 4.35 (H-1'), 3.77 (H-2), 3.65 (H-5'), 3.47 (H-4), 3.23 (H-2'), 3.09 (6-OCH₃), 2.57 (H-8), 2.57 (H-7a), 2.50 (H-3'), 2.28 /3'-N(CH₃)₂/, 2.02 (H-14a), 1.72 (10-CH₃), 1.70 (H-4'a), 1.58 (H-14b), 1.43 (H-7b), 1.38 (4-CH₃), 1.33* (6-CH₃), 1.31 (2-CH₃), 1.28 (5'-CH₃), 1.22* (12-CH₃), 1.21 (H-4'b), 1.11 (8-CH₃), 0.89 (15-CH₃).

^{13}C NMR (75 MHz, CDCl_3) δ 211.0 (C-11), 208.5 (C-3), 179.0 (C-9)*, 172.4* (C-1), 102.8 (C-1'), 79.6* (C-12), 79.1* (C-6), 76.7 (C-13), 73.8 (C-5), 70.0 (C-2'), 69.1 (C-5'), 65.5 (C-3'), 53.6 (C-10), 49.2 (6-OCH₃), 48.5 (C-2), 44.9 (C-4), 40.0 /3'-N(CH₃)₂/, 38.8 (C-7), 32.7 (C-8), 28.2 (C-4'), 21.1 (5'-CH₃), 20.4 (C-14), 18.8** (12-CH₃), 18.6** (6-CH₃), 17.7 (8-CH₃), 16.1 (10-CH₃), 14.3 (4-CH₃), 13.3 (2-CH₃), 10.5 (15-CH₃).

FAB-MS m/z 601 (MH^+).

Example 9

3-Decladinosyl-3-oxy-6-*O*-methyl-8a-aza-8a-homoerythromycin A

11,12-cyclic carbonate

To ethyl acetate (15 ml) there were added 3-decladinosyl-3-oxy-6-*O*-methyl-8a-aza-8a-homoerythromycin A (1.9 g, 0.0031 mole) obtained according to the process described in PCT/HR 99/00004, 4/99, K₂CO₃ (2.5 g, 0.0018 mole) and ethylene carbonate (5.5 g, 0.063 mole), and then the reaction mixture was stirred for 10 hours at the temperature 90 °C. To the reaction mixture again ethylene carbonate (2.5 g) was added and it was stirred for further 7 hours at the same temperature. Into the cooled reaction mixture water (30 ml) was added, the layers were separated and the aqueous one was extracted with CH₂Cl₂ (2x30 ml). The combined organic extracts were dried over K₂CO₃ and evaporated under reduced pressure, yielding a crude residue (2.5 g). By chromatography on a silica gel column using the system CH₂Cl₂-CH₃OH-conc.NH₄OH, 90:4:0.5, a chromatographically homogenous title product (1.3 g) was obtained.

IR (KBr) cm^{-1} 3444, 2975, 2940, 2833, 1817, 1733, 1651, 1545, 1461, 1384, 1340, 1235, 1165, 1111, 1082, 1049.

^1H NMR (600 MHz, CDCl_3) δ 5.90 (8a-CONH), 5.27 (H-13), 4.53 (H-11), 4.40 (H-1'), 3.99 (H-3), 3.88 (H-5), 3.77 (H-8), 3.55 (H-5'), 3.24 (H-2'), 3.12 (6-OCH₃), 2.60 (H-2), 2.51 (H-10), 2.49 (H-3'), 2.26 /3'-N(CH₃)₂/, 1.76 (H-14a), 1.70 (H-7a), 1.67 (H-4'a), 1.67 (H-14b), 1.65 (H-7b), 1.61 (H-4), 1.37 (12-CH₃), 1.34 (10-CH₃), 1.32 (6-CH₃), 1.30 (2-CH₃), 1.29 (8-CH₃), 1.26 (5'-CH₃), 1.25 (H-4'b), 1.01 (4-CH₃), 0.93 (15-CH₃).

^{13}C NMR (150 MHz, CDCl_3) δ 175.5 (C-1), 170.4 (C-9), 153.1 (C=O carbonate), 106.9 (C-1'), 91.7 (C-5), 86.8 (C-12), 82.9 (C-11), 79.1 (C-6), 76.8 (C-3), 74.8 (C-13), 70.4 (C-2'), 69.8 (C-5'), 65.5 (C-3'), 49.3 (6-OCH₃), 43.9 (C-2), 43.8 (C-8), 42.5 (C-10), 41.1 (C-7), 40.2 /3'-N(CH₃)₂/, 37.1 (C-4), 28.1 (C-4'), 22.2 (C-14), 21.7 (8-CH₃), 21.3 (6-CH₃), 20.8 (5'-CH₃), 16.3 (12-CH₃), 15.6 (2-CH₃), 14.8 (10-CH₃), 10.2 (15-CH₃), 7.9 (4-CH₃).

FAB-MS m/z 631 (MH^+).

Example 10

2'-O-Acetyl-3-decladinosyl-3-oxy-6-O-methyl-8a-aza-8a-homoerythromycin A 11,12-cyclic carbonate

To a mixture of solvents CH_2Cl_2 (10 ml) and acetone (1 ml), 3-decladinosyl-3-oxy-6-O-methyl-8a-aza-8a-homoerythromycin A 11,12-cyclic carbonate (0.75 g, 0.0012 mole) from the Example 9, NaHCO_3 (0.5 g, 0.0059 mole) and acetic acid anhydride (0.28 ml, 0.003 mole) were added and it was stirred for 3 hours at room temperature. To the reaction mixture a saturated NaHCO_3 solution (10 ml) was added, the layers were separated and the aqueous layer was extracted with CH_2Cl_2 (2x20 ml). The combined organic extracts were rinsed with a saturated NaCl solution, dried over K_2CO_3 and evaporated at a reduced pressure, yielding the title product (0.8 g).

IR (KBr) cm^{-1} 3389, 2975, 2940, 1813, 1741, 1659, 1540, 1458, 1374, 1237, 1166, 1058.

^1H NMR (600 MHz, CDCl_3) δ 6.22 (8a-CONH), 5.16 (H-13), 4.78 (H-2'), 4.63 (H-1'), 4.53 (H-11), 3.89 (H-8), 3.84 (H-5), 3.83 (H-3), 3.54 (H-5'), 3.13 (6-OCH₃), 2.87 (H-3'), 2.61 (H-2), 2.49 (H-10), 2.30 /3'-N(CH₃)₂/, 2.09 (COCH₃), 1.82 (H-14a), 1.80 (H-7a), 1.78 (H-4'a), 1.75 (H-4), 1.64 (H-14b), 1.60 (H-7b), 1.39 (12-CH₃), 1.36 (H-4'b), 1.32 (10-CH₃), 1.28 (2-CH₃), 1.26 (6-CH₃), 1.26 (5'-CH₃), 1.23 (8-CH₃), 0.92 (15-CH₃), 0.91 (4-CH₃).

^{13}C NMR (150 MHz, CDCl_3) δ 174.7 (C-1), 170.6 (C-9), 170.3 (COCH₃), 153.2 (C=O carbonate), 101.5 (C-1'), 86.3 (C-5), 85.5 (C-12), 82.4 (C-11), 78.6 (C-6), 76.0 (C-3), 75.5 (C-13), 71.3 (C-2'), 68.8 (C-5'), 63.0 (C-3'), 49.9 (6-OCH₃), 43.8 (C-2), 42.5 (C-8), 42.4 (C-10), 41.1 (C-7), 40.0 /3'-N(CH₃)₂/, 37.7 (C-4), 30.5 (C-4'), 22.1 (C-8), 22.1 (C-14), 21.4 (6-CH₃), 21.2 (COCH₃), 21.0 (5'-CH₃), 15.7 (12-CH₃), 15.3 (2-CH₃), 13.9 (10-CH₃), 10.1 (4-CH₃), 8.2 (15-CH₃).

Example 11

3-Decladinosyl-3-O-(4-nitrophenyl)acetyl-6-O-methyl-8a-aza-8a-homoerythromycin A 11,12-cyclic carbonate

By reacting 2'-O-acetyl-3-decladinosyl-3-oxy-6-O-methyl-8a-aza-8a-homo-erythromycin A 11,12-cyclic carbonate (0.3 g, 0.0004 mole) obtained according to the process described in the Example 10, 4-nitrophenyl acetic acid (0.263 g, 0.0015 mole) and pivaloyl chloride (0.180 ml, 0.0015 mole), according to the process described in the Example 6, a chromatographically homogeneous title product with the following physical-chemical constants was obtained:

IR (KBr) cm^{-1} 3437, 2976, 2940, 1809, 1666, 1524, 1459, 1348, 1233, 1166, 1111.

^1H NMR (600 MHz, CDCl_3) δ 8.20 and 7.52 (Ph), 6.19 (8a-CONH), 5.47 (H-3), 5.01 (H-13), 4.47 (H-11), 4.05 (H-1'), 3.92 (H-8), 3.84 and 3.80 (PhCH₂), 3.74 (H-5), 3.30 (H-5'), 3.20 (6-OCH₃), 3.16 (H-2'), 2.83 (H-2), 2.48 (H-10), 2.38 (H-3'), 2.28 /3'-N(CH₃)₂/, 2.09 (COCH₃), 2.07 (H-4), 1.86 (H-14a), 1.83 (H-7a), 1.63 (H-4'a), 1.61

(H-14b), 1.55 (H-7b), 1.44 (12-CH₃), 1.31 (10-CH₃), 1.30 (6-CH₃), 1.19 (H-4'b), 1.20 (5'-CH₃), 1.24 (8-CH₃), 1.02 (2-CH₃), 0.91 (15-CH₃), 0.8 (4-CH₃).

¹³C NMR (150 MHz, CDCl₃) δ 173.5* (C-1), 170.8* (C-9), 169.8* (3-OCOCH₂-), 153.1 (C=O carbonate), 147.2, 141.2, 130.5, 123.7 (Ph), 103.9 (C-1'), 85.9 (C-12), 82.4 (C-5), 82.0 (C-11), 79.0 (C-6), 76.7 (C-3), 76.0 (C-13), 70.3 (C-2'), 69.6 (C-5'), 65.9 (C-3'), 50.7 (6-OCH₃), 43.8 (C-2), 43.1 (C-10), 43.0 (C-8), 41.7 (C-7), 41.2 (-CH₂Ph), 40.3 /3'-N(CH₃)₂/, 38.4 (C-4), 28.3 (C-4'), 22.3 (8-CH₃), 22.3 (C-14), 21.3 (6-CH₃), 21.1 (5'-CH₃), 15.0 (12-CH₃), 14.2 (2-CH₃), 13.8 (10-CH₃), 10.6 (4-CH₃), 10.2 (15-CH₃).

FAB-MS m/z 794 (MH⁺).

Example 12

3-Decladinosyl-3-O-(4-nitrophenyl)acetyl-6-O-methyl-8a-aza-8a-homoerythromycin A

By reacting 2'-O-acetyl-3-decladinosyl-3-oxy-6-O-methyl-8a-aza-8a-homoerythromycin A (0.3 g, 0.0004 mole) obtained according to the process described in PCT/HR 99/00004, 4/99, 4-nitrophenyl acetic acid (0.263 g, 0.0015 mole), pivaloyl chloride (0.180 ml, 0.0015 mole) and triethylamine (0.202 ml, 0.0015 mole), according to the process described in the Example 6, a chromatographically homogeneous title product with the following physical-chemical constants was obtained:

IR (KBr) cm⁻¹ 3440, 2976, 2937, 1741, 1651, 1525, 1461, 1348, 1168, 1076, 1050.

FAB-MS m/z 768 (MH⁺).

¹H NMR (600 MHz, CDCl₃) δ 8.20 (d, Ph), 7.54 (Ph), 5.91 (8a-CONH), 5.38 (H-3), 5.03 (H-13), 3.96 (H-1'), 3.87 (PhCH₂), 3.82 (H-8), 3.81 (PhCH₂), 3.74 (H-5), 3.42 (H-11), 3.25 (H-5'), 3.19 (H-2'), 3.19 (6-OMe), 2.77 (H-2), 2.38 (H-10), 2.33 (H-3'), 2.27 /3'-N(CH₃)₂/, 2.14 (H-4), 1.92 (H-14a), 1.86 (H-7a), 1.60 (H-4'a), 1.51 (H-7b), 1.47 (H-14b), 1.29 (6-CH₃), 1.24 (8-CH₃), 1.19 (10-CH₃), 1.19 (H-4'b), 1.18 (5'-CH₃), 1.13 (4-CH₃), 1.10 (12-CH₃), 0.92 (2-CH₃), 0.84 (15-CH₃).

^{13}C NMR (150 MHz, CDCl_3) δ 174.9 (C-9), 174.7 (C-1), 169.7 (3-OCOCH₂-), 147.2, 141.1, 130.4, 123.7 (Ph), 104.1 (C-1'), 83.3 (C-5), 78.7 (C-3), 78.6 (C-13), 77.5 (C-6), 74.8 (C-12), 70.5 (C-11), 70.4 (C-2'), 69.6 (C-5'), 66.1 (C-3'), 51.0 (6-OCH₃), 43.2 (C-2), 42.9 (C-10), 42.6 (C-8), 42.2 (C-7), 41.3 (-CH₂Ph), 40.3 /3'-N(CH₃)₂/, 37.1 (C-4), 28.3 (C-4'), 23.1 (8-CH₃), 21.3 (C-14), 21.1 (5'-CH₃), 20.9 (6-CH₃), 16.3 (12-CH₃), 15.6 (2-CH₃), 10.8 (15-CH₃), 10.1 (10-CH₃), 9.53 (4-CH₃).

Example 13

3-Decladinosyl-3-*O*-(4-chlorophenyl)acetyl-6-*O*-methyl-8a-aza-8a-homoerythromycin A 11,12-cyclic carbonate

By reacting 2'-*O*-acetyl-3-decladinosyl-3-oxy-6-*O*-methyl-8a-aza-8a-homoerythromycin A 11,12-cyclic carbonate (0.2 g, 0.0003 mole) obtained according to the process described in the Example 10, 4-chlorophenyl acetic acid (0.330 g, 0.0019 mole), pivaloyl chloride (0.239 ml, 0.0019 mole) and triethyl amine (0.270 ml, 0.0019 mole) over 3 days at room temperature according to the process described in the Example 6, a chromatographically homogenous title product with the following physical-chemical constants was obtained:

IR (KBr) cm^{-1} 3388, 2976, 2941, 2883, 2787, 1812, 1744, 1667, 1541, 1493, 1458, 1380, 1357, 1332, 1234, 1165, 1111, 1051, 1017, 981.

FAB-MS m/z 783 (MH^+).

Example 14

3-Decladinosyl-3-*O*-(4-methoxyphenyl)acetyl-6-*O*-methyl-8a-aza-8a-homoerythromycin A

By reacting 2'-*O*-acetyl-3-decladinosyl-3-oxy-6-*O*-methyl-8a-aza-8a-homoerythromycin A (0.250 g, 0.0004 mole) obtained according to the process described in PCT/HR 99/00004, 4/99, 4-methoxyphenyl acetic acid (0.321 g, 0.0019 mole), pivaloyl chloride (0.239 ml, 0.0019 mole) and triethylamine (0.270 ml, 0.0019 mole)

over 5 days at room temperature according to the process described in the Example 6, a chromatographically homogeneous title product was obtained:

IR (KBr) cm^{-1} 3444, 2975, 2939, 2836, 2787, 1740, 1651, 1514, 1462, 1379, 1337, 1257, 1167, 1110, 1076, 1035, 984, 959.

FAB-MS m/z 753 (MH^+)

Example 15

3-Decladinosyl-3-oxo-6-*O*-methyl-8a-aza-8a-homoerythromycin A 11,12-cyclic carbonate


To a solution of 2'-*O*-acetyl-3-decladinosyl-3-oxy-6-*O*-methyl-8a-aza-8a-homoerythromycin A 11,12-cyclic carbonate from the Example 10 (0.4 g, 0.00059 mole) in CH_2Cl_2 (20 ml) dimethyl sulfoxide (0.7 ml) and *N,N*-dimethyl-aminopropyl-ethylcarbodiimide (0.7 g, 0.0036 mole) were added. The reaction mixture was cooled to 15°C, under stirring and maintaining the temperature a solution of pyridinium trifluoroacetate (0.7 g, 0.0036 mole) in CH_2Cl_2 (5 ml) was added drop by drop over 15 minutes, the temperature of the reaction mixture was raised to room temperature and the reaction was kept stirring over night. After the addition of a saturated NaCl solution (30 ml) and CH_2Cl_2 (30 ml), the reaction mixture was alkalized to pH 10 (2 *N* NaOH) and extracted with CH_2Cl_2 . The organic extracts were rinsed with a saturated NaCl solution and water, dried over K_2CO_3 and evaporated at a reduced pressure, yielding 0,5 g of an oily residue, which was subjected to methanolysis (30 ml) at room temperature for 24 hours. Methanol was evaporated at a reduced pressure, the obtained residue (0.49 g) was purified by low-pressure chromatography on a silica gel column using chloroform and then solvent system CH_2Cl_2 - CH_3OH -conc. NH_4OH , 90:4:0.5 yielding a chromatographically homogeneous title product with the following physical-chemical constants:

IR (KBr) cm^{-1} 3379, 2976, 1814, 1755, 1713, 1668, 1539, 1457, 1381, 1243, 1166, 1110, 1062, 995.

FAB-MS m/z 629 (MH^+).

Claims

1. Novel 15-membered 8a- and 9a-lactams from the class of 6-*O*-methyl-erythromycin A of the general formula (I)




their pharmaceutically acceptable addition salts with inorganic or organic acids and their hydrates, wherein

A stands for NH group and **B** simultaneously stands for C=O group, or

A stands for C=O group and **B** simultaneously stands for NH group,

R¹ stands for OH group, L-cladinosyl group of formula (II)



or R^1 stands for a group of formula (III),



wherein

Y stands for hydrogen, C₁-C₆ alkyl, C₁-C₆ alkyl group with at least one incorporated O, N or S atom or **Y** stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n is 1-10, with or without incorporated O, N or S atoms, and **Ar** stands for a 5-10-membered monocyclic or bicyclic aromatic ring containing 0-3 O, N or S atoms, which is unsubstituted or substituted with 1-3 groups representing halogen, OH, OMe, NO₂, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl, CN, SO₂NH₂, C₁-C₃ alkyl, or

R¹ together with **R**² stands for ketone,

R² stands for hydrogen or together with **R**¹ stands for ketone,



R³ stands for hydrogen or C₁-C₄ alkanoyl group,

R⁴ stands for hydrogen or together with **R**⁵ stands for ketone,

R⁵ stands for OH, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl, O(CH₂)_nAr or S(CH₂)_nAr, wherein (CH₂)_n and Ar have the above meanings, or together with **R**⁴ stands for ketone,

R⁶ stands for hydrogen, C₁-C₆ alkyl, C₁-C₆ alkyl group with at least one incorporated O, N or S atom, or (CH₂)_n-Ar group, wherein (CH₂)_n and Ar have the above meanings, or

R⁵ and **R**⁶ together with intervening atoms form an additional ring of formula (IV)



wherein

Z stands for CH₂, C=O, C(NH), SO, SO₂, CH₂CO, COCH₂, CH₂CH₂CO, COCH₂CH₂ or CH₂CH₂, and

X stands for hydrogen, C₁-C₃ alkyl, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl or (CH₂)_n-Ar group, wherein (CH₂)_n and Ar have the above meanings.

2. A compound according to claim 1, *characterized in that* A stands for NH and B simultaneously stands for C=O group, R¹ stands for L-cladinosyl group of formula (II) and R², R³ and R⁴ are mutually the same and stand for hydrogen, R⁵ and R⁶ together with intervening atoms form an additional ring of formula (IV), wherein Z stands for CH₂, C=O, C(NH), SO, SO₂, CH₂CO, COCH₂, CH₂CH₂CO, COCH₂CH₂ or CH₂CH₂, and X stands for hydrogen, C₁-C₃ alkyl, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl or (CH₂)_n-Ar group, wherein (CH₂)_n and Ar have the meanings given in claim 1.
3. A compound according to claim 2, *characterized in that* A stands for NH group and B simultaneously stands for C=O group, R¹ stands for L-cladinosyl group of formula (II) and R², R³ and R⁴ are mutually the same and stand for hydrogen, R⁵ and R⁶ together with intervening atoms form an additional ring of formula (IVb), wherein Z stands for C=O group.
4. A compound according to claim 1, *characterized in that* A stands for C=O group and B simultaneously stands for NH group, R¹ stands for L-cladinosyl group of formula (II) and R², R³ and R⁴ are mutually the same and stand for hydrogen, R⁵ and R⁶ together with intervening atoms form an additional ring of formula (IV), wherein Z stands for CH₂, C=O, C(NH), SO, SO₂, CH₂CO, COCH₂, CH₂CH₂CO, COCH₂CH₂ or CH₂CH₂, and X stands for hydrogen, C₁-C₃ alkyl, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl or (CH₂)_n-Ar group, wherein (CH₂)_n and Ar have the meanings given in claim 1.

5. A compound according to claim 4, *characterized in that* A stands for C=O group and B simultaneously stands for NH group, R^1 stands for L-cladinosyl group of formula (II) and R^2 , R^3 and R^4 are mutually the same and stand for hydrogen, R^5 and R^6 together with intervening atoms form an additional ring of formula (IVb), wherein Z stands for C=O group.
6. A compound according to claim 1, *characterized in that* A stands for NH group and B simultaneously stands for C=O group, R^1 stands for OH and R^2 , R^3 and R^4 are mutually the same and stand for hydrogen, R^5 and R^6 together with intervening atoms form an additional ring of formula (IV), wherein Z stands for CH_2 , C=O, C(NH), SO, SO_2 , CH_2CO , $COCH_2$, CH_2CH_2CO , $COCH_2CH_2$ or CH_2CH_2 , and X stands for hydrogen, C_1 - C_3 alkyl, NH_2 , amino- C_1 - C_3 alkyl or amino- C_1 - C_3 - dialkyl or $(CH_2)_n$ -Ar group, wherein $(CH_2)_n$ and Ar have the meanings given in claim 1.
7. A compound according to claim 6, *characterized in that* A stands for NH group and B simultaneously stands for C=O group, R^1 stands for OH and R^2 , R^3 and R^4 are mutually the same and stand for hydrogen, R^5 and R^6 together with intervening atoms form an additional ring of formula (IVb), wherein Z stands for C=O group.
8. A compound according to claim 1, *characterized in that* A stands for NH group and B simultaneously stands for C=O group, R^1 stands for OH, and R^2 and R^4 are mutually the same and stand for hydrogen, R^3 stands for C_1 - C_4 alkanoyl group, R^5 and R^6 together with intervening atoms form an additional ring of formula (IVb), wherein Z stands for C=O group.
9. A compound according to claim 8, *characterized in that* A stands for NH group and B simultaneously stands for C=O group, R^1 stands for OH, and R^2 and R^4 are mutually the same and stand for hydrogen, R^3 stands for acetyl group, R^5 and R^6

together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O group.

10. A compound according to claim 1, *characterized in that* **A** stands for C=O group and **B** simultaneously stands for NH group, **R**¹ stands for OH and **R**², **R**³ and **R**⁴ are mutually the same and stand for hydrogen, **R**⁵ and **R**⁶ together with intervening atoms form an additional ring of formula (IV), wherein **Z** stands for CH₂, C=O, C(NH), SO, SO₂, CH₂CO, COCH₂, CH₂CH₂CO, COCH₂CH₂ or CH₂CH₂, and **X** stands for hydrogen, C₁-C₃ alkyl, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃- dialkyl or (CH₂)_n-Ar group, wherein (CH₂)_n and Ar have the meanings given in claim 1.
11. A compound according to claim 10, *characterized in that* **A** stands for C=O group and **B** simultaneously stands for NH group, **R**¹ stands for OH and **R**², **R**³ and **R**⁴ are mutually the same and stand for hydrogen, **R**⁵ and **R**⁶ together with intervening atoms form an additional ring of formula (IV), wherein **Z** stands for C=O group.
12. A compound according to claim 1, *characterized in that* **A** stands for C=O group and **B** simultaneously stands for NH group, **R**¹ stands for OH, **R**² and **R**⁴ are mutually the same and stand for hydrogen, **R**³ stands for C₁-C₄ alkanoyl group, **R**⁵ and **R**⁶ together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O group.
13. A compound according to claim 12, *characterized in that* **A** stands for C=O group and **B** simultaneously stands for NH group, **R**¹ stands for OH, **R**² and **R**⁴ are mutually the same and stand for hydrogen, **R**³ stands for acetyl group, **R**⁵ and **R**⁶ together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O group.

14. A compound according to claim 1, *characterized in that* **A** stands for NH group and **B** simultaneously stands for C=O group, R^1 stands for a group of formula (III), wherein **Y** stands for hydrogen, C₁-C₆ alkyl, C₁-C₆ alkyl group with at least one incorporated O, N or S atom, or **Y** stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n is 1-10, without or with incorporated O, N or S atoms, and **Ar** stands for a 5-10-membered monocyclic or bicyclic aromatic ring comprising 0-3 O, N or S atoms which is unsubstituted or substituted with 1-3 groups representing halogen, OH, OMe, NO₂, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl, CN, SO₂NH₂, C₁-C₃ alkyl, R^2 , R^3 and R^4 are mutually the same and stand for hydrogen, R^5 and R^6 together with intervening atoms form an additional ring of formula (IV), wherein **Z** stands for CH₂, C=O, C(NH), SO, SO₂, CH₂CO, COCH₂, CH₂CH₂CO, COCH₂CH₂ or CH₂CH₂, and **X** stands for hydrogen, C₁-C₃ alkyl, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl or (CH₂)_n-Ar group, wherein (CH₂)_n and Ar have the above meanings.
15. A compound according to claim 14, *characterized in that* **A** stands for NH group and **B** simultaneously stands for C=O group, R^1 stands for a group of formula (III) wherein **Y** stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n is 1 and **Ar** stands for 6-membered monocyclic aromatic ring substituted with *p*-NO₂ group, R^2 , R^3 and R^4 are mutually the same and stand for hydrogen, R^5 and R^6 together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O.
16. A compound according to claim 14, *characterized in that* **A** stands for NH group and **B** simultaneously stands for C=O group, R^1 stands for a group of formula (III) wherein **Y** stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n is 1 and **Ar** stands for 6-membered monocyclic aromatic ring substituted with *p*-OCH₃ group, R^2 , R^3 and R^4 are mutually the same and stand for hydrogen, R^5 and R^6 together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O.

17. A compound according to claim 14, *characterized in that* **A** stands for NH group and **B** simultaneously stands for C=O group, **R**¹ stands for a group of formula (III) wherein **Y** stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n is 1 and **Ar** stands for a 6-membered monocyclic aromatic ring substituted with *p*-NH₂ group, **R**², **R**³ and **R**⁴ are mutually the same and stand for hydrogen, **R**⁵ and **R**⁶ together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O.
18. A compound according to claim 14, *characterized in that* **A** stands for NH group and **B** simultaneously stands for C=O group, **R**¹ stands for a group of formula (III) wherein **Y** stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n is 1 and **Ar** stands for 6-membered monocyclic aromatic ring substituted with *p*-OH group, **R**², **R**³ and **R**⁴ are mutually the same and stand for hydrogen, **R**⁵ and **R**⁶ together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O.
19. A compound according to claim 14, *characterized in that* **A** stands for NH group and **B** simultaneously stands for C=O group, **R**¹ stands for a group of formula (III) wherein **Y** stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n is 1 and **Ar** stands for 6-membered monocyclic aromatic ring substituted with *p*-Cl, **R**², **R**³ and **R**⁴ are mutually the same and stand for hydrogen, **R**⁵ and **R**⁶ together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O.
20. A compound according to claim 14, *characterized in that* **A** stands for NH group and **B** simultaneously stands for C=O group, **R**¹ stands for a group of formula (III) wherein **Y** stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n is 1 and **Ar** stands for 6-membered monocyclic aromatic ring substituted with *p*-SO₂NH₂, **R**², **R**³ and **R**⁴ are mutually the same and stand for hydrogen, **R**⁵ and

R^6 together with intervening atoms form an additional ring of formula (IVb), wherein Z stands for $C=O$.

21. A compound according to claim 14, *characterized in that* A stands for NH group and B simultaneously stands for $C=O$ group, R^1 stands for a group of formula (III) wherein Y stands for $(CH_2)_n-Ar$, wherein $(CH_2)_n$ stands for alkyl and n is 1 and Ar stands for 6-membered monocyclic aromatic ring substituted with $p-NH-(CH_3)$ group, R^2 , R^3 and R^4 are mutually the same and stand for hydrogen, R^5 and R^6 together with intervening atoms form an additional ring of formula (IVb), wherein Z stands for $C=O$.
22. A compound according to claim 14, *characterized in that* A stands for NH group and B simultaneously stands for $C=O$ group, R^1 stands for a group of formula (III) wherein Y stands for $(CH_2)_n-Ar$, wherein $(CH_2)_n$ stands for alkyl and n is 1 and Ar stands for 6-membered monocyclic aromatic ring substituted with $p-N(CH_3)_2$ group, R^2 , R^3 and R^4 are mutually the same and stand for hydrogen, R^5 and R^6 together with intervening atoms form an additional ring of formula (IVb), wherein Z stands for $C=O$.
23. A compound according to claim 14, *characterized in that* A stands for NH group and B simultaneously stands for $C=O$ group, R^1 stands for a group of formula (III) wherein Y stands for $(CH_2)_n-Ar$, wherein $(CH_2)_n$ stands for alkyl and n is 1 and Ar stands for 6-membered monocyclic aromatic ring substituted with $p-CH_3$ group, R^2 , R^3 and R^4 are mutually the same and stand for hydrogen, R^5 and R^6 together with intervening atoms form an additional ring of formula (IVb), wherein Z stands for $C=O$.
24. A compound according to claim 1, *characterized in that* A stands for $C=O$ group and B simultaneously stands for NH group, R^1 stands for a group of formula (III), Y stands for hydrogen, C_1-C_6 alkyl, C_1-C_6 alkyl group with at least one

incorporated O, N or S atom, or Y stands for $(CH_2)_n$ -Ar, wherein $(CH_2)_n$ stands for alkyl and n is 1-10, without or with incorporated O, N or S atoms, and Ar stands for 5-10-membered monocyclic or bicyclic aromatic ring comprising 0-3 O, N or S atoms which is unsubstituted or substituted with 1-3 groups representing halogen, OH, OMe, NO₂, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl, CN, SO₂NH₂, C₁-C₃ alkyl, R², R³ and R⁴ are mutually the same and stand for hydrogen, R⁵ and R⁶ together with intervening atoms form an additional ring of formula (IV), wherein Z stands for CH₂, C=O, C(NH), SO, SO₂, CH₂CO, COCH₂, CH₂CH₂CO, COCH₂CH₂ or CH₂CH₂, and X stands for hydrogen, C₁-C₃ alkyl, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl or $(CH_2)_n$ -Ar group, wherein $(CH_2)_n$ and Ar have the above meanings.

25. A compound according to claim 24, *characterized in that* A stands for C=O group and B simultaneously stands for NH group, R¹ stands for a group of formula (III) wherein Y stands for $(CH_2)_n$ -Ar, wherein $(CH_2)_n$ stands for alkyl and n is 1 and Ar stands for 6-membered monocyclic aromatic ring substituted with *p*-NO₂ group, R², R³ and R⁴ are mutually the same and stand for hydrogen, R⁵ and R⁶ together with intervening atoms form an additional ring of formula (IVb), wherein Z stands for C=O.
26. A compound according to claim 24, *characterized in that* A stands for C=O group and B simultaneously stands for NH group, R¹ stands for a group of formula (III) wherein Y stands for $(CH_2)_n$ -Ar, wherein $(CH_2)_n$ stands for alkyl and n is 1 and Ar stands for 6-membered monocyclic aromatic ring substituted with *p*-OCH₃ group, R², R³ and R⁴ are mutually the same and stand for hydrogen, R⁵ and R⁶ together with intervening atoms form an additional ring of formula (IVb), wherein Z stands for C=O.
27. A compound according to claim 24, *characterized in that* A stands for C=O group and B simultaneously stands for NH group, R¹ stands for a group of formula (III)

wherein **Y** stands for $(\text{CH}_2)_n\text{-Ar}$, wherein $(\text{CH}_2)_n$ stands for alkyl and n is 1 and **Ar** stands for 6-membered monocyclic aromatic ring substituted with $p\text{-NH}_2$ group, R^2 , R^3 and R^4 are mutually the same and stand for hydrogen, R^5 and R^6 together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O .

28. A compound according to claim 24, *characterized in that* **A** stands for C=O group and **B** simultaneously stands for NH group, R^1 stands for a group of formula (III) wherein **Y** stands for $(\text{CH}_2)_n\text{-Ar}$, wherein $(\text{CH}_2)_n$ stands for alkyl and n is 1 and **Ar** stands for 6-membered monocyclic aromatic ring substituted with $p\text{-OH}$ group, R^2 , R^3 and R^4 are mutually the same and stand for hydrogen, R^5 and R^6 together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O .
29. A compound according to claim 24, *characterized in that* **A** stands for C=O group and **B** simultaneously stands for NH group, R^1 stands for a group of formula (III) wherein **Y** stands for $(\text{CH}_2)_n\text{-Ar}$, wherein $(\text{CH}_2)_n$ stands for alkyl and n is 1 and **Ar** stands for 6-membered monocyclic aromatic ring substituted with $p\text{-Cl}$, R^2 , R^3 and R^4 are mutually the same and stand for hydrogen, R^5 and R^6 together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O .
30. A compound according to claim 24, *characterized in that* **A** stands for C=O group and **B** simultaneously stands for NH group, R^1 stands for a group of formula (III) wherein **Y** stands for $(\text{CH}_2)_n\text{-Ar}$, wherein $(\text{CH}_2)_n$ stands for alkyl and n is 1 and **Ar** stands for 6-membered monocyclic aromatic ring substituted with $p\text{-SO}_2\text{NH}_2$, R^2 , R^3 and R^4 are mutually the same and stand for hydrogen, R^5 and R^6 together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O .

31. A compound according to claim 24, *characterized in that* **A** stands for C=O group and **B** simultaneously stands for NH group, **R**¹ stands for a group of formula (III) wherein **Y** stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n is 1 and **Ar** stands for 6-membered monocyclic aromatic ring substituted with *p*-NH-(CH₃) group, **R**², **R**³ and **R**⁴ are mutually the same and stand for hydrogen, **R**⁵ and **R**⁶ together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O.
32. A compound according to claim 24, *characterized in that* **A** stands for C=O group and **B** simultaneously stands for NH group, **R**¹ stands for a group of formula (III) wherein **Y** stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n is 1 and **Ar** stands for 6-membered monocyclic aromatic ring substituted with *p*-N(CH₃)₂ group, **R**², **R**³ and **R**⁴ are mutually the same and stand for hydrogen, **R**⁵ and **R**⁶ together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O.
33. A compound according to claim 24, *characterized in that* **A** stands for C=O group and **B** simultaneously stands for NH group, **R**¹ stands for a group of formula (III) wherein **Y** stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n is 1 and **Ar** stands for 6-membered monocyclic aromatic ring substituted with *p*-CH₃ group, **R**², **R**³ and **R**⁴ are mutually the same and stand for hydrogen, **R**⁵ and **R**⁶ together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O.
34. A compound according to claim 1, *characterized in that* **A** stands for NH group and **B** simultaneously stands for C=O group, **R**¹ has the meaning of the group of the formula (III), wherein **Y** stands for hydrogen, C₁-C₆ alkyl, C₁-C₆ alkyl group with at least one incorporated O, N or S atom, or **Y** stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n stands for 1-10, without or with incorporated O, N or S atoms, and **Ar** stands for 5-10-membered monocyclic or bicyclic aromatic ring

containing 0-3 O, N or S atoms, which is unsubstituted or substituted with 1-3 groups representing halogen, OH, OMe, NO₂, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl, CN, SO₂NH₂, C₁-C₃ alkyl, R², R³, R⁴, and R⁶ are mutually the same and stand for hydrogen and R⁵ is OH group.

35. A compound according to claim 34, *characterized in that* A stands for NH group and B simultaneously stands for C=O group, R¹ has the meaning of the group of the formula (III), wherein Y stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n stands for 1 and Ar stands for 6-membered monocyclic aromatic ring substituted with *p*-NO₂ group, R², R³, R⁴, and R⁶ are mutually the same and stand for hydrogen and R⁵ is OH.
36. A compound according to claim 34, *characterized in that* A stands for NH group and B simultaneously stands for C=O group, R¹ has the meaning of the group of the formula (III), wherein Y stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n stands for 1 and Ar stands for 6-membered monocyclic aromatic ring substituted with *p*-OCH₃ group, R², R³, R⁴, and R⁶ are mutually the same and stand for hydrogen and R⁵ is OH.
37. A compound according to claim 34, *characterized in that* A stands for NH group and B simultaneously stands for C=O group, R¹ has the meaning of the group of the formula (III), wherein Y stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n stands for 1 and Ar stands for 6-membered monocyclic aromatic ring substituted with *p*-NH₂ group, R², R³, R⁴, and R⁶ are mutually the same and stand for hydrogen and R⁵ is OH.
38. A compound according to claim 34, *characterized in that* A stands for NH group and B simultaneously stands for C=O group, R¹ has the meaning of the group of the formula (III), wherein Y stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n stands for 1 and Ar stands for 6-membered monocyclic aromatic ring

substituted with *p*-OH group, R^2 , R^3 , R^4 , and R^6 are mutually the same and stand for hydrogen and R^5 is OH.

39. A compound according to claim 34, *characterized in that* **A** stands for NH group and **B** simultaneously stands for C=O group, R^1 has the meaning of the group of the formula (III), wherein **Y** stands for $(CH_2)_n$ -Ar, wherein $(CH_2)_n$ stands for alkyl and *n* stands for 1 and **Ar** stands for 6-membered monocyclic aromatic ring substituted with *p*-Cl, R^2 , R^3 , R^4 , and R^6 are mutually the same and stand for hydrogen and R^5 is OH.
40. A compound according to claim 34, *characterized in that* **A** stands for NH group and **B** simultaneously stands for C=O group, R^1 has the meaning of the group of the formula (III), wherein **Y** stands for $(CH_2)_n$ -Ar, wherein $(CH_2)_n$ stands for alkyl and *n* stands for 1 and **Ar** stands for 6-membered monocyclic aromatic ring substituted with *p*-SO₂NH₂, R^2 , R^3 , R^4 , and R^6 are mutually the same and stand for hydrogen and R^5 is OH.
41. A compound according to claim 34, *characterized in that* **A** stands for NH group and **B** simultaneously stands for C=O group, R^1 has the meaning of the group of the formula (III), wherein **Y** stands for $(CH_2)_n$ -Ar, wherein $(CH_2)_n$ stands for alkyl and *n* stands for 1 and **Ar** stands for 6-membered monocyclic aromatic ring substituted with *p*-NH-CH₃ group, R^2 , R^3 , R^4 , and R^6 are mutually the same and stand for hydrogen and R^5 is OH.
42. A compound according to claim 34, *characterized in that* **A** stands for NH group and **B** simultaneously stands for C=O group, R^1 has the meaning of the group of the formula (III), wherein **Y** stands for $(CH_2)_n$ -Ar, wherein $(CH_2)_n$ stands for alkyl and *n* stands for 1 and **Ar** stands for 6-membered monocyclic aromatic ring substituted with *p*-N(CH₃)₂ group, R^2 , R^3 , R^4 , and R^6 are mutually the same and stand for hydrogen and R^5 is OH.

43. A compound according to claim 34, *characterized in that* A stands for NH group and B simultaneously stands for C=O group, R^1 has the meaning of the group of the formula (III), wherein Y stands for $(CH_2)_n$ -Ar, wherein $(CH_2)_n$ stands for alkyl and n stands for 1 and Ar stands for 6-membered monocyclic aromatic ring substituted with *p*-CH₃ group, R^2 , R^3 , R^4 , and R^6 are mutually the same and stand for hydrogen and R^5 is OH.
44. A compound according to claim 1, *characterized in that* A stands for C=O group and B simultaneously stands for NH group, R^1 has the meaning of the group of the formula (III), wherein Y stands for hydrogen, C₁-C₆ alkyl, C₁-C₆ alkyl group with at least one incorporated O, N or S atom, or Y stands for $(CH_2)_n$ -Ar, wherein $(CH_2)_n$ stands for alkyl and n stands for 1-10, without or with incorporated O, N or S atoms, and Ar stands for 5-10-membered monocyclic or bicyclic aromatic ring containing 0-3 O, N or S atoms, which is unsubstituted or substituted with 1-3 groups representing halogen, OH, OMe, NO₂, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl, CN, SO₂NH₂, C₁-C₃ alkyl, R^2 , R^3 , R^4 , and R^6 are mutually the same and stand for hydrogen and R^5 is OH group.
45. A compound according to claim 44, *characterized in that* A stands for C=O group and B simultaneously stands for NH group, R^1 has the meaning of the group of the formula (III), wherein Y stands for $(CH_2)_n$ -Ar, wherein $(CH_2)_n$ stands for alkyl and n stands for 1 and Ar stands for 6-membered monocyclic aromatic ring substituted with *p*-NO₂ group, R^2 , R^3 , R^4 , and R^6 are mutually the same and stand for hydrogen and R^5 is OH.
46. A compound according to claim 44, *characterized in that* A stands for C=O group and B simultaneously stands for NH group, R^1 has the meaning of the group of the formula (III), wherein Y stands for $(CH_2)_n$ -Ar, wherein $(CH_2)_n$ stands for alkyl and n stands for 1 and Ar stands for 6-membered monocyclic aromatic ring

substituted with *p*-OCH₃ group, R², R³, R⁴, and R⁶ are mutually the same and stand for hydrogen and R⁵ is OH.

47. A compound according to claim 44, *characterized in that* A stands for C=O group and B simultaneously stands for NH group, R¹ has the meaning of the group of the formula (III), wherein Y stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n stands for 1 and Ar stands for 6-membered monocyclic aromatic ring substituted with *p*-NH₂ group, R², R³, R⁴, and R⁶ are mutually the same and stand for hydrogen and R⁵ is OH.
48. A compound according to claim 44, *characterized in that* A stands for C=O group and B simultaneously stands for NH group, R¹ has the meaning of the group of the formula (III), wherein Y stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n stands for 1 and Ar stands for 6-membered monocyclic aromatic ring substituted with *p*-OH group, R², R³, R⁴, and R⁶ are mutually the same and stand for hydrogen and R⁵ is OH.
49. A compound according to claim 44, *characterized in that* A stands for C=O group and B simultaneously stands for NH group, R¹ has the meaning of the group of the formula (III), wherein Y stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n stands for 1 and Ar stands for 6-membered monocyclic aromatic ring substituted with *p*-Cl, R², R³, R⁴, and R⁶ are mutually the same and stand for hydrogen and R⁵ is OH.
50. A compound according to claim 44, *characterized in that* A stands for C=O group and B simultaneously stands for NH group, R¹ has the meaning of the group of the formula (III), wherein Y stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n stands for 1 and Ar stands for 6-membered monocyclic aromatic ring substituted with *p*-SO₂NH₂, R², R³, R⁴, and R⁶ are mutually the same and stand for hydrogen and R⁵ is OH.


51. A compound according to claim 44, *characterized in that* A stands for C=O group and B simultaneously stands for NH group, R^1 has the meaning of the group of the formula (III), wherein Y stands for $(CH_2)_n$ -Ar, wherein $(CH_2)_n$ stands for alkyl and n stands for 1 and Ar stands for 6-membered monocyclic aromatic ring substituted with *p*-NH-CH₃ group, R^2 , R^3 , R^4 , and R^6 are mutually the same and stand for hydrogen and R^5 is OH.
52. A compound according to claim 44, *characterized in that* A stands for C=O group and B simultaneously stands for NH group, R^1 has the meaning of the group of the formula (III), wherein Y stands for $(CH_2)_n$ -Ar, wherein $(CH_2)_n$ stands for alkyl and n stands for 1 and Ar stands for 6-membered monocyclic aromatic ring substituted with *p*-N(CH₃)₂ group, R^2 , R^3 , R^4 , and R^6 are mutually the same and stand for hydrogen and R^5 is OH.
53. A compound according to claim 44, *characterized in that* A stands for C=O group and B simultaneously stands for NH group, R^1 has the meaning of the group of the formula (III), wherein Y stands for $(CH_2)_n$ -Ar, wherein $(CH_2)_n$ stands for alkyl and n stands for 1 and Ar stands for 6-membered monocyclic aromatic ring substituted with *p*-CH₃ group, R^2 , R^3 , R^4 , and R^6 are mutually the same and stand for hydrogen and R^5 is OH.
54. A compound according to claim 1, *characterized in that* A stands for NH group and B simultaneously stands for C=O group, R^1 and R^2 together stand for a ketone, R^3 and R^6 are mutually the same and stand for hydrogen and R^4 and R^5 together stand for a ketone.
55. A compound according to claim 1, *characterized in that* A stands for C=O group and B simultaneously stands for NH group, R^1 and R^2 together stand for a ketone,

R^3 and R^6 are mutually the same and stand for hydrogen and R^4 and R^5 together stand for a ketone.

56. A compound according to claim 1, *characterized in that* A stands for NH group and B simultaneously stands for C=O group, R^1 and R^2 together stand for a ketone, R^3 and R^4 are mutually the same and stand for hydrogen, R^5 and R^6 together with intervening atoms form an additional ring of formula (IV), wherein Z stands for CH_2 , C=O, C(NH), SO, SO_2 , CH_2CO , $COCH_2$, CH_2CH_2CO , $COCH_2CH_2$ or CH_2CH_2 , and X stands for hydrogen, C_1 - C_3 alkyl, NH_2 , amino- C_1 - C_3 alkyl or amino- C_1 - C_3 dialkyl or $(CH_2)_n$ -Ar group, wherein $(CH_2)_n$ and Ar have the meanings given in claim 1.
57. A compound according to claim 56, *characterized in that* A stands for NH group and B simultaneously stands for C=O group, R^1 and R^2 together stand for a ketone, R^3 and R^4 are mutually the same and stand for hydrogen, R^5 and R^6 together with intervening atoms form an additional ring of formula (IVb), wherein Z stands for C=O.
58. A compound according to claim 1, *characterized in that* A stands for C=O group and B simultaneously stands for NH group, R^1 and R^2 together stand for a ketone, R^3 and R^4 are mutually the same and stand for hydrogen, R^5 and R^6 together with intervening atoms form an additional ring of formula (IV), wherein Z stands for CH_2 , C=O, C(NH), SO, SO_2 , CH_2CO , $COCH_2$, CH_2CH_2CO , $COCH_2CH_2$ or CH_2CH_2 , and X stands for hydrogen, C_1 - C_3 alkyl, NH_2 , amino- C_1 - C_3 alkyl or amino- C_1 - C_3 dialkyl or $(CH_2)_n$ -Ar group, wherein $(CH_2)_n$ and Ar have the meanings given in claim 1.
59. A compound according to claim 1, *characterized in that* A stands for C=O group and B simultaneously stands for NH group, R^1 and R^2 together stand for a ketone, R^3 and R^4 are mutually the same and stand for hydrogen, R^5 and R^6 together with

intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O.

60. A process for preparation of novel 15-membered 8a- and 9a-lactams from the class of 6-*O*-methyl-erythromycin A of general formula (I),




of their pharmaceutically acceptable addition salts with inorganic or organic acids and their hydrates, wherein

A stands for NH group and **B** simultaneously stands for C=O group, or

A stands for C=O group and **B** simultaneously stands for NH group,

R¹ stands for OH group, L-cladinosyl group of formula (II)



or **R¹** stands for a group of formula (III),



wherein

Y stands for hydrogen, C₁-C₆ alkyl, C₁-C₆ alkyl group with at least one incorporated O, N or S atom or **Y** stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n stands for 1-10, with or without incorporated O, N or S atoms, and **Ar** stands for 5-10-membered monocyclic or bicyclic aromatic ring containing 0-3 O, N or S atoms, which is unsubstituted or substituted with 1-3 groups representing halogen, OH, OMe, NO₂, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl, CN, SO₂NH₂, C₁-C₃ alkyl, or

R¹ together with **R**² stands for ketone,

R² stands for hydrogen or together with **R**¹ stands for ketone,



R³ stands for hydrogen or C₁-C₄ alkanoyl group,

R⁴ stands for hydrogen or together with **R**⁵ stands for ketone,

R⁵ stands for OH, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl, O(CH₂)_nAr or S(CH₂)_nAr, wherein (CH₂)_n and Ar have the above meanings, or together with **R**⁴ stands for ketone,

R⁶ stands for hydrogen, C₁-C₆ alkyl, C₁-C₆ alkyl group with at least one incorporated O, N or S atom, or (CH₂)_n-Ar group, wherein (CH₂)_n and Ar have the above meanings, or

R⁵ and **R**⁶ together with intervening atoms form an additional ring of formula (IV)



wherein

Z stands for CH₂, C=O, C(NH), SO, SO₂, CH₂CO, COCH₂, CH₂CH₂CO, COCH₂CH₂ or CH₂CH₂, and

X stands for hydrogen, C₁-C₃ alkyl, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl or (CH₂)_n-Ar group, wherein (CH₂)_n and Ar have the above meanings,

characterized in that,

A/

- a) 6-*O*-methyl-9a-aza-9a-homoerythromycin A or 6-*O*-methyl-8a-aza-8a-homoerythromycin A of the general formula (I), wherein A stands for NH group and B simultaneously stands for C=O group, or A stands for C=O group and B simultaneously stands for NH group, R¹ stands for L-cladinosyl group of the formula (II) and R², R³, R⁴ and R⁶ are mutually the same and stand for hydrogen and R⁵ stands for OH group, obtained according to PCT/HR 99/00004, 4/99, are subjected to a reaction with ethylene carbonate in the presence of inorganic or organic bases, preferably potassium carbonate, in a reaction-inert solvent, preferably in ethyl acetate, yielding corresponding 11,12-cyclic carbonates of the general formula (I), wherein A stands for NH group and B simultaneously stands for C=O group, or A stands for C=O group and B simultaneously stands for NH group, R¹ stands for L-cladinosyl group of the formula (II) and R², R³ and R⁴ are mutually the same and stand for hydrogen, R⁵ and R⁶ together with intervening atoms form an additional ring of the formula (IVb), wherein Z stands for C=O group, which are subsequently subjected to
- b) hydrolysis with strong acids, preferably with 0.25-1.5 N hydrochloric acid, in a mixture of water and lower alcohols, preferably methanol, ethanol or isopropanol, over 10-30 hours at room temperature, yielding 3-decladinosyl derivatives of the general formula (I), wherein A stands for NH group and B simultaneously stands

for C=O group, or **A** stands for C=O group and **B** simultaneously stands for NH group, **R**¹ stands for OH group, **R**², **R**³ and **R**⁴ are mutually the same and stand for hydrogen, and **R**⁵ and **R**⁶ together with intervening atoms form an additional ring of the formula (IVb), wherein **Z** stands for C=O group, which are subsequently subjected to

- c) a selective acylation of a hydroxyl group in 2'-position with chlorides or anhydrides of carboxylic acids with up to 4 carbon atoms, preferably with acetic acid anhydride, in the presence of inorganic or organic bases such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate, triethyl amine, pyridine, tributylamine, preferably sodium hydrogen carbonate, in a reaction-inert solvent such as methylene chloride, dichloroethane, acetone, pyridine, ethyl acetate, tetrahydrofuran, preferably methylene chloride, at a temperature from 0 - 30 °C, yielding 2'-O-acyl derivatives of the general formula (I), wherein **A** stands for NH group and **B** simultaneously stands for C=O group, or **A** stands for C=O group and **B** simultaneously stands for NH group, **R**¹ stands for OH group, **R**² and **R**⁴ are mutually the same and stand for hydrogen, **R**³ stands for acetyl and **R**⁵ and **R**⁶ together with intervening atoms form an additional ring of formula (IVb), wherein **Z** stands for C=O group, which are optionally subjected to
- d1) a reaction with mixed anhydrides of carboxylic acids of formula Y-COO-R', wherein **Y** stands for hydrogen, C₁-C₆ alkyl, C₁-C₆ alkyl group with at least one incorporated O, N or S atom, or **Y** stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n is 1-10, without or with incorporated O, N or S atoms, and **Ar** stands for 5-10-membered monocyclic or bicyclic aromatic ring comprising 0-3 O, N or S atoms which is unsubstituted or substituted with 1-3 groups representing halogen, OH, OMe, NO₂, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl, CN, SO₂NH₂, C₁-C₃ alkyl and **R'** represents a group which is usually used for the preparation of mixed anhydrides such as pivaloyl, p-toluenesulfonyl, isobutoxycarbonyl, ethoxycarbonyl or isopropoxycarbonyl groups, in the presence of

inorganic or organic bases, in a reaction-inert solvent, preferably in methylene chloride, at a temperature from 0-30 °C over 3-100 hours, yielding 3-acyl derivatives of the general formula (I), wherein R^1 stands for a group of formula (III), Y has the above meanings, A stands for NH group and B simultaneously stands for C=O group, or A stands for C=O group and B simultaneously stands for NH group, R^2 and R^4 are mutually the same and stand for hydrogen, R^3 stands for acetyl and R^5 and R^6 together with intervening atoms form an additional ring of formula (IVb), wherein Z stands for C=O group, which are subsequently subjected to deprotection with lower alcohols, preferably in methanol, at a temperature from room temperature to the reflux temperature of the solvent, yielding a compound of the general formula (I), wherein R^3 stands for hydrogen and all remaining substituents have the above meanings,

or to

- d2) oxidation of a hydroxyl group in C-3 position of the aglycone ring according to a modified Moffat-Pfitzner process with *N,N*-dimethyl aminopropyl-3-ethyl-carbodiimide in the presence of dimethyl sulfoxide and pyridinium trifluoroacetate as catalyst, in an inert organic solvent, preferably in methylene chloride, at a temperature from 10°C to room temperature, yielding 3-oxo derivatives of the general formula (I), wherein A stands for NH group and B simultaneously stands for C=O group, or A stands for C=O group and B simultaneously stands for NH group, R^1 together with R^2 stands for ketone, R^3 stands for acetyl group, R^4 stands for hydrogen and R^5 and R^6 together with intervening atoms form an additional ring of formula (IVb), wherein Z stands for C=O group, which are subsequently subjected to deprotection in lower alcohols, preferably in methanol, at a temperature from room temperature to the reflux temperature of the solvent, yielding a compound of the general formula (I), wherein R^3 stands for hydrogen and all remaining substituents have the above meanings,

or

B/

a) 6-*O*-methyl-9a-aza-9a-homoerythromycin **A** or 6-*O*-methyl-8a-aza-8a-homoerythromycin **A** of the general formula (I), wherein **A** stands for NH group and **B** simultaneously stands for C=O group, or **A** stands for C=O group and **B** simultaneously stands for NH group, **R**¹ stands for L-cladinosyl group of the formula (II) and **R**², **R**³, **R**⁴ and **R**⁶ are mutually the same and stand for hydrogen and **R**⁵ stands for OH group, obtained according to PCT/HR 99/00004, 4/99, are subjected to hydrolysis with strong acids, then to a selective acylation of 2'-position, which are then optionally subjected to

b1) a reaction with mixed anhydrides and deprotection as given above, yielding a compound of the general formula (I), wherein **R**¹ has the meaning of a group of the formula (III), wherein **Y** stands for hydrogen, C₁-C₆ alkyl, C₁-C₆ alkyl group with at least one incorporated O, N or S atom, or **Y** stands for (CH₂)_n-Ar, wherein (CH₂)_n stands for alkyl and n is 1-10, without or with incorporated O, N or S atoms, and **Ar** stands for a 5-10-membered monocyclic or bicyclic aromatic ring containing 0-3 O, N or S atoms, which is unsubstituted or substituted with 1-3 groups representing halogen, OH, OMe, NO₂, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl, CN, SO₂NH₂, C₁-C₃ alkyl, **R**², **R**³, **R**⁴, and **R**⁶ are mutually the same and stand for hydrogen and **R**⁵ is OH group,

or to

b2) oxidation of hydroxyl groups in C-3 and C-11 positions of an aglycone ring according to a modified Moffat-Pfitzner process as given above, and deprotection, yielding a compound of the general formula (I), wherein **A** stands for NH group and **B** simultaneously stands for C=O group, or **A** stands for C=O group and **B** simultaneously stands for NH group, **R**¹ together with **R**² stands for a ketone, **R**³

and R^6 are mutually the same and stand for hydrogen and R^4 together with R^5 stands for a ketone,

or

alternatively, compounds obtained according to the process **Ad1)** can be prepared by subjecting the compounds from the step **Bb1)** to a reaction with ethylene carbonate in a manner as described in **Aa)**,

or

alternatively, compounds from the step **Ab)** can be obtained by changing the sequence of the reaction steps in such a manner that 6-*O*-methyl-9a-aza-9a-homoerythromycin A or 6-*O*-methyl-8a-aza-8a-homoerythromycin A obtained according to PCT/HR 99/00004, 4/99, are first subjected to hydrolysis with strong acids as described in **Ab)** and then to a reaction with ethylene carbonate in a manner described in **Aa)**,


or

alternatively, the compounds from **Ad2)** can be obtained in such a manner that 3-decladinosyl-3-oxo-6-*O*-methyl-9a-aza-9a-homoerythromycin A or 3-decladinosyl-3-oxo-6-*O*-methyl-8a-aza-8a-homo-erythromycin A, obtained according to PCT/HR 99/00004, 4/99, are subjected to a reaction with ethylene carbonate in a manner described in the step **Aa)**,

and for obtaining their pharmaceutically acceptable addition salts, the novel compounds from the class of 6-*O*-methyl-9a-aza-9a-homo- and 6-*O*-methyl-8a-aza-8a-homo-erythromycins A of the general formula (I), wherein A, B, R^1 , R^2 , R^3 , R^4 , R^5 and R^6 have the above meanings, are reacted with an at least equimolar amount of a suitable inorganic or organic acid such as hydrochloric, hydroiodic,

sulfuric, phosphoric, acetic, propionic, trifluoroacetic, maleic, citric, stearic, succinic, ethylsuccinic, methanesulfonic, benzenesulfonic, p-toluenesulfonic, laurylsulfonic acid and the like, in a reaction-inert solvent, and by isolating by means of filtration if they are insoluble in the reaction-inert solvent, or precipitation by means of a non-solvent or of evaporation of the solvent, most frequently by lyophilization.

61. Pharmaceutical composition useful for treatment of bacterial infections in humans and animals comprising therapeutically effective amounts of a compound of general formula (I) or its pharmaceutically acceptable addition salts according to claim 1, in combination with a pharmaceutically acceptable carrier.
62. Method for treating bacterial infections in humans and animals comprising administering to humans and animals required therapeutically effective amounts of a compound of the general formula (I) or pharmaceutically acceptable addition salts thereof according to claim 1, in combination with a pharmaceutically acceptable carrier.



wherein

Y stands for hydrogen, C₁-C₆ alkyl, C₁-C₆ alkyl group with at least one incorporated O, N or S atom or **Y** stands for (CH₂)_n-Ar wherein (CH₂)_n stands for alkyl and n stands for 1-10, with or without incorporated O, N or S atoms, and **Ar** stands for 5-10-membered monocyclic or bicyclic aromatic ring containing 0-3 O, N or S atoms, which is unsubstituted or substituted with 1-3 groups representing halogen, OH, OMe, NO₂, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl, CN, SO₂NH₂, C₁-C₃ alkyl, or

R¹ together with **R**² stands for ketone,

R² stands for hydrogen or together with **R**¹ stands for ketone,



R³ stands for hydrogen or C₁-C₄ alkanoyl group,

R⁴ stands for hydrogen or together with **R**⁵ stands for ketone,

R⁵ stands for OH, NH₂, amino-C₁-C₃ alkyl or amino-C₁-C₃ dialkyl, O(CH₂)_nAr or S(CH₂)_nAr, wherein (CH₂)_n and Ar have the above meanings, or together with **R**⁴ stands for ketone,

R⁶ stands for hydrogen, C₁-C₆ alkyl, C₁-C₆ alkyl group with at least one incorporated O, N or S atom, or (CH₂)_n-Ar group, wherein (CH₂)_n and Ar have the above meanings, or

R⁵ and **R**⁶ together with intervening atoms form an additional ring of formula (IV)



wherein

Z stands for CH_2 , $\text{C}=\text{O}$, $\text{C}(\text{NH})$, SO , SO_2 , CH_2CO , COCH_2 , $\text{CH}_2\text{CH}_2\text{CO}$, COCH_2CH_2 or CH_2CH_2 , and

X stands for hydrogen, $\text{C}_1\text{-C}_3$ alkyl, NH_2 , amino- $\text{C}_1\text{-C}_3$ alkyl or amino- $\text{C}_1\text{-C}_3$ dialkyl or $(\text{CH}_2)_n\text{-Ar}$ group, wherein $(\text{CH}_2)_n$ and Ar have the above meanings,

to intermediates for their preparation, to a process for their preparation, to their pharmaceutically acceptable addition salts with inorganic or organic acids, to their hydrates, to a process for the preparation of pharmaceutical compositions as well as to a use of pharmaceutical compositions for the treatment of bacterial infections.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/HR 00/00009

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07H17/08 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07H A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 99 19331 A (MORGAN JERRY D II ; SANTORELLI GINA M (US); MERCK & CO INC (US); BL) 22 April 1999 (1999-04-22) the whole document	1-62
P, X	WO 99 51616 A (KELNERI & CACUTE ; KOBREHEL GABRIJELA (HR); LAZAREVSKI GORJANA (HR)) 14 October 1999 (1999-10-14) the whole document	1-62
Y	WO 97 42204 A (ABBOTT LAB) 13 November 1997 (1997-11-13) claim 1	1-62
Y	EP 0 467 331 A (PLIVA PHARM & CHEM WORKS) 22 January 1992 (1992-01-22) claim 1	1-62
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 July 2000

Date of mailing of the international search report

22/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Bardili, W

INTERNATIONAL SEARCH REPORT

Inter: nal Application No

PCT/HR 00/00009

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,Y	DENIS, A. AND C. AGOURIDAS: "Synthesis of 6-O-methyl azithromycin and its keto analogue" BIOORG. MED. CHEM. LETT., vol. 8, 1998, pages 2427-2432, XP004138245 page 2429-30; compound 3 -----	1-62

INTERNATIONAL SEARCH REPORT

International Application No
PCT/HR 00/00009

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9919331 A	22-04-1999	AU 1082599 A	03-05-1999
WO 9951616 A	14-10-1999	AU 3046499 A	25-10-1999
WO 9742204 A	13-11-1997	AU 2340797 A	26-11-1997
		AU 2998797 A	26-11-1997
		BR 9708929 A	03-08-1999
		CZ 9803518 A	14-04-1999
		EP 0918783 A	02-06-1999
		EP 1007530 A	14-06-2000
		WO 9742206 A	13-11-1997
		US 6075011 A	13-06-2000
EP 0467331 A	22-01-1992	AT 129715 T	15-11-1995
		BG 60593 B	29-09-1995
		CA 2046956 A,C	19-01-1992
		CN 1059728 A,B	25-03-1992
		CS 9102195 A	18-03-1992
		DE 69114198 D	07-12-1995
		DE 69114198 T	27-06-1996
		DK 467331 T	05-02-1996
		ES 2081397 T	01-03-1996
		GR 3018330 T	31-03-1996
		HR 920491 A	31-08-1994
		HU 59935 A	28-07-1992
		HU 215158 B	28-12-1998
		HU 9500748 A	28-12-1995
		JP 2657132 B	24-09-1997
		JP 5132497 A	28-05-1993
		PL 166379 B	31-05-1995
		RO 109338 A	30-01-1995
		SI 9011409 A	31-10-1995
		SK 279075 B	03-06-1998
		RU 2045533 C	10-10-1995
		US 5250518 A	05-10-1993